Skip to main content
Makoto Onizuka on Muck Rack

Makoto Onizuka

As seen in: Nature, Wiley Online Library
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Makoto

Contact Makoto, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Seven security challenges in cross-domain multi-agent LLM systems

|
By Jiseong Chung, Shuyuan Zheng, Chuan Xiao, Tae-Wan Kim, Makoto Onizuka, Won-Yong Shin, Ronny Ko
| Nature Verified
Abstract Large language models are evolving into autonomous agents that collaborate across organizations for tasks like disaster response and supply-chain optimization. However, such cooperation breaks unified trust assumptions: a benign agent may leak secrets or violate policy when interacting with untrusted peers.
Open in Who Shared Issue with article?

Impact of antiviral therapies on survival in patients with HHV-6B encephalitis after cord blood transplantation: a real-world study

|
By Toshiki Terao, Wataru Kitamura, Takahiro Fujino, Naoyuki Uchida, Masatsugu Tanaka, Atsushi Wake, Masahito Tokunaga, Keisuke Kataoka, Masashi Sawa, Makoto Onizuka, Masako Toyosaki, Koichi Onodera, Tetsuya Nishida, Yuta Katayama, Takeshi Maeda, Yuta Hasegawa, Shunya Arai, Makoto Yoshimitsu, Takahiro Fukuda, Marie Ohbiki, Yoshiko Atsuta, Kimikazu Yakushijin, Masao Ogata, Hideki Nakasone, Takami Haruyama, Yuri Okazoe
| Nature Verified
Abstract In this registry-based study, we evaluated the efficacy of different antiviral therapies for adult patients who developed human herpesvirus-6B (HHV-6B) encephalitis after their first cord blood transplantation (CBT). Among 3,862 CBT recipients registered in Japan between January 2019 and December 2023, HHV-6B encephalitis occurred in 289 patients within 100 days post-transplant (7.5%).
Open in Who Shared Issue with article?

Retrospective analysis of clinical outcomes and risk factors in hematopoietic cell transplantation for relapsed or refractory mantle cell lymphoma in the post-ibrutinib era

|
By Satoshi Yamasaki, Yutaka Shimazu, Yukiko Misaki, Makoto Onizuka, Masashi Sawa, Yoshinobu Kanda, Takahiro Fukuda, Makoto Yoshimitsu, Junya Kanda, Yoshiko Atsuta, Shinichi Kako, Chizuko Hashimoto
| Nature Verified
Abstract Ibrutinib, a Bruton tyrosine kinase inhibitor, has improved outcomes for patients with relapsed or refractory mantle cell lymphoma, yet prognosis remains inadequate for many. The choice between high-dose therapy with autologous hematopoietic cell transplantation (HCT) and allogeneic HCT remains a topic of debate in this patient population.
Open in Who Shared Issue with article?
See all 29 articles